Agios Pharma (AGIO) Misses Q2 EPS by 9c

Agios Pharma (NASDAQ: AGIO) reported Q2 EPS of ($1.69), $0.09 worse than the analyst estimate of ($1.60). Revenue for the quarter came in at $8.62 million versus the consensus estimate of $9.26 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Cantor Fitzgerald Upgrades Capricor Therapeutics (CAPR) to Overweight
• Bernstein SocGen Group Upgrades Wayfair (W) to Outperform